Steroid derivative FXR agonist

A compound represented by formula (III),

• wherein,
• ring A is selected from 5- to 12-membered aryl, 5- to 12-membered heteroaryl, 5_to 6-membered non-aromatic heterocyclyl, or 5- to 6-membered cycloalkyl;
• and said ring A is optionally substituted with 1, 2 or 3 of R;
• L is selected from C1-6 alkyl, C1-6 heteroalkyl, or C2-6 alkenyl, and said L is optionally substituted with 1, 2 or 3 of R;
• R is selected from F, Cl, Br, I, OH, CN, NO2, NH2, C1-3 all ylamino;
• N,N-di(C1-3 alkyl)amino, C1-3 alkyl, C1-3 alkyloxy, or C1-3 alkylthio, and said R is optionally substituted with 1, 2 or 3 R′;
• R′ is selected from F, Cl, Br, I, OH, NH2, NO2, CN, COOH, Me, Et, CH2F, CHF2, CF3, CH3O, CH3S, NH(CH3), or N(CH3)2;
• said “hetero” represents heteroatom or heteroatomic group, selected from —C(═O)NH—, N, —NH—, —C(═NH)—, —S(═O)2NH—, —S(═O)NH—, —O—, —S—, ═O, ═S, —C(═O)C—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2—, or —NHC(═O)NH—;
• in any of the above cases, the number of the heteroatom or heteroatomic groups is independently selected from 1, 2 or 3;
• or a pharmaceutically acceptable salt thereof.